- Home
- TVGN vs TIL Comparison
TVGN vs TIL Comparison
Compare TVGN & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | TIL |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 74.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVGN | TIL |
|---|---|---|
| Price | $0.33 | $10.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 1.5M | 57.3K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $10.17 |
| 52 Week High | $1.92 | $42.79 |
Technical Indicators
Market Signals| Indicator | TVGN | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 40.84 |
| Support Level | $0.30 | $10.17 |
| Resistance Level | $0.41 | $11.60 |
| Average True Range (ATR) | 0.03 | 0.60 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 23.04 | 42.86 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.